Discontinued — last reported Q4 '23
Business Segments · Property, plant and equipment, net
Covance Drug Development — Property, plant and equipment, net
Labcorp Holdings Covance Drug Development — Property, plant and equipment, net decreased by 1.1% to $1.11B in Q4 2023 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2023
Rolls up toPP&E (Net)
How to read this metric
An increase indicates ongoing investment in infrastructure and capacity expansion for the segment.
Detailed definition
The net book value of physical assets, such as laboratories and testing equipment, used by the drug development segment....
Peer comparison
Standard measure of capital intensity for laboratory and clinical research organizations.
Metric ID:
lh_segment_covance_drug_development_property_plant_and_equipment_netHistorical Data
3 periods
| Q4 '21 | Q4 '22 | Q4 '23 | |
|---|---|---|---|
| Value | $1.31B | $1.12B | $1.11B |
| QoQ Change | — | -14.0% | -1.1% |
| YoY Change | — | -14.0% | -1.1% |
Range$1.11B – $1.31B
Avg YoY Growth-7.5%
Median YoY Growth-7.5%
Current Streak2+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — property, plant and equipment, net?
- Labcorp Holdings (LH) reported covance drug development — property, plant and equipment, net of $1.11B in Q4 2023.
- What does covance drug development — property, plant and equipment, net mean?
- The current value of the segment's physical buildings and equipment.